Clinical Trial

Safety and Preliminary Efficacy of HN2302 in Patients With Autoimmune Diseases

Study acronym: AID
Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is an open-label, single-arm study designed to evaluate the safety and preliminary efficacy of HN2302 in patients with autoimmune diseases, including systemic lupus erythematosus (SLE) and systemic sclerosis (SSc).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-04-04.
Trial Details
NCT Number NCT07523282
Lead Sponsor Shenzhen MagicRNA Biotechnology Co., Ltd
Collaborators: The First Affiliated Hospital of University of Science and Technology of China
Conditions Autoimmune Disease, Systemic Lupus Erythematosus, Systemic Sclerosis (SSc)
Enrollment 12 participants
Start Date 2026-12-31
Primary Completion 2027-12-31 (estimated)
Study Completion 2028-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-12